Paricalcitol versus placebo for reduction of proteinuria in kidney transplant recipients: a double-blind, randomized controlled trial
Author:
Affiliation:
1. Department of Nephrology; University Medical Centre Ljubljana; Ljubljana Slovenia
2. Faculty of Medicine; University of Ljubljana; Ljubljana Slovenia
Funder
Javna Agencija za Raziskovalno Dejavnost RS
University Medical Centre Ljubljana
AbbVie
Publisher
Frontiers Media SA
Subject
Transplantation
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/tri.13323/fullpdf
Reference54 articles.
1. Long-term renal allograft survival in the United States: a critical reappraisal;Lamb;Am J Transplant,2011
2. Kidney function and risk of cardiovascular disease and mortality in kidney transplant recipients: the FAVORIT trial;Weiner;Am J Transplant,2012
3. High mortality in the first year after kidney graft failure;Buturović-Ponikvar;Transplant Proc,2013
4. Respective predictive role of urinary albumin excretion and nonalbumin proteinuria on graft loss and death in renal transplant recipients;Halimi;Am J Transplant,2007
5. The clinical significance of early proteinuria after renal transplantation;Cherukuri;Transplantation,2010
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Vitamin D3 Improves Adipose Stromal Cell Survival and Human Fat Graft Retention in Xenograft Model;Stem Cells and Development;2024-09-01
2. Therapeutic approaches and novel antifibrotic agents in renal fibrosis: A comprehensive review;Journal of Biochemical and Molecular Toxicology;2024-08
3. Sequential administration of paricalcitol followed by IL-17 blockade for progressive refractory IgA nephropathy patients;Scientific Reports;2024-02-28
4. Antiproteinuric effect of paricalcitol in kidney transplant recipients with severe proteinuria: a prospective cohort study;Journal of Nephrology;2022-07-28
5. Paricalcitol versus Calcitriol + Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease in China: A Cost-Effectiveness Analysis;Frontiers in Public Health;2021-07-21
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3